Abstract
Introduction
"The child who tastes salty will soon die" -German folklore. A series of events that took place during the very hot summer of 1938 in New York City led to the recognition of a new disease, Cystic fibrosis (CF). Dr. Dorothea Anderson 1 noted that a number of children presented to Columbia Hospital with severe dehydration, but without diarrhea or vomiting. Several of these children had been followed in the gastrointestinal clinic for failure to thrive and greasy stool, many also had coughed. Thus began the recognition of Cystic fibrosis (CF) of the pancreas. By 1946, the genetic nature of this autosomal recessive disorder was described. In 1953, Dr. Paul di Sant' Agnese recognized that CF patients lost excessive salt in their sweat, 2 forming the basis for use of the sweat chloride test as a cornerstone of the diagnosis of the disease.
Cystic fibrosis (CF), also known as mucovisidosis, is a genetic disorder that affects mostly the lungs but also the pancreas, liver, kidney, intestines. It is an autosomal recessive disorder caused by the presence of mutations in both copies of the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). 3 Those with single working copy are carriers and otherwise mostly normal. 4 CFTR is involved in production of sweat, digestive fluids and mucus. 5 When CFTR is not functional, secretions which are usually thin instead become thick. 6 This condition is diagnosed by sweat test and genetic testing. Screening at birth takes places in some areas of the world. There is no cure for CF. Lung infections are treated with antibiotics which may be given intravenously, inhaled or by mouth. Inhaled hypertonic saline and salbutamol may also be useful. Pancreatic enzyme replacement and soluble vitamin supplementation are important especially in the young. Many people use airway clearance technique such as chest physiotherapy. 3 The average life expectancy is between 37 to 50 years in the developed world. 7 Lung problems are responsible for death in 80% of people with CF.
Epidemiology
Cystic fibrosis is the most common life-limiting autosomal recessive disorder among people of European heritage. 8 In the United States (US), approximately 30,000 individuals have CF; most are diagnosed by six months of age. Approximately 1 in 25 people of European descent, and 1 in 30 of Caucasian American, are a carrier of CF mutation. 9 Although CF is less common in these groups, approximately 1 in 46 Hispanics, 1 in 65 Africans and 1 in 90 Asian carry at least one abnormal cystic fibrosis transmembrane conductance regulator (CFTR) gene. 10 Ireland has the world's highest prevalence of CF at 1:1353. 11 World Health Organization (WHO) states that "In the European Union, 1 in 2000-3000 newborn is found to be affected by CF". 12 In the US, 1 in 3500 children is born with CF. 13 CF is diagnosed in both males and females equally.
Etiology/genetics
Typically, CF is caused by two lesions in the CFTR gene, which gives rise to a generalized exocrine disease of the respiratory, gastrointestinal, reproductive, hepato-biliary tract. 15 The CF mutations have been localized to chromosome 7, band q31. 16, 17 the locus codes for a transport protein named the CFTR. 18 More than 800 mutations are now found. The Caucasian associated delta F508 defect is the most common mutation found. The genetic variations and molecular implications are becoming clearer. 19 The protein product of the cystic fibrosis transmembrane conductance regulator (CFTR) gene is a chloride channel expressed in the apical membrane of epithelial cells. 20 
Pathophysiology
The name Cystic fibrosis (CF) refers to the characteristic fibrosis and cysts that form within the pancrease 1 . There are several mutations in the CFTR gene; the different mutations cause different defects in the CFTR protein, sometimes causing a milder or more severe disease. The CFTR protein is anchored to the outer membrane of cells in the sweat glands, lungs, pancreas and all other remaining exocrine gland of the body and acts as a channel connecting the inner part of the cells (cytoplasm) to the surrounding fluid. The channel is primarily responsible for controlling the movement of halogens from inside to the outside of the cells; however, in the sweat ducts, it facilitates the movement of chloride from the sweat duct into cytoplasm. When the CFTR protein does not resorb ions in sweat ducts, chloride and thiocynate inside the ducts and pumped into the skin. Because chloride is negatively charged, this creates a difference in the electrical potential inside and outside the cells causing catpoms to cross into the cell. The excess chloride within the sweat ducts prevents sodium desorption by epithelial sodium channels and the combination of sodium and chloride creates the salt, which is lost in high amounts in the sweats of several of individuals with CF. This lost salt forms the basis for the sweat tests. 20 
Clinical manifestations
The main signs and symptoms of CF are salt testing skin, 21 poor growths and poor weight gain despite normal food intake, 22 accumulation of thick, sticky mucus 23 , frequent chest infections and coughing or shortness of breath. 24 In a review of CF patients, the frequency of presenting signs and symptoms were: acute or persistent respiratory illness (51%), failure to thrive or malnutrition (43%), abnormal stool or steatorrhoea (35%), meconium ileus or intestinal obstruction (19%), family history of CF (17%), electrolyte imbalance (5%), hepatobiliary disease (91%) and prenatal diagnosis by chorionic villus sampling or amniocentesis (1%). signs and symptoms often appear in infancy and childhood, such as bowel obstruction due to meconium ileus in newborn babies. 26 The poor growth in children typically presents as an inability to gain weight or height at the same rate as their peers. The causes of growth failure are multifactorial and include chronic illness. 27 
Diagnosis
Cystic fibrosis (CF) may be diagnosed by many different methods which include followings 28 29 The most consistent aspect of therapy in CF is limiting and treating the lung damage caused by thick mucus and infection, with the goal of maintaining quality of life. Intravenous, inhaled and oral antibiotics are used to treat chronic and acute infections. Mechanical devices and inhalation medications are used to alter and clear the thickened mucus. Many patients with CF are on one or more antibiotics at all times, even when healthy, to prophylactically suppress infection. 33 Several mechanical techniques are used to dislodge sputum and encourage its expectoration. In the hospital setting, chest physiotherapy (CPT) is utilized; a respiratory therapist percusses an individual's chest with hands several times a day to lossen up secretions. Devices that recreate this percussive therapy include the THAIRapy Vest and the intrapulmonary percussive ventilator (IPV). 34 Treatment of pancreatic insufficiency by replacement of missing digestive enzymes allows the duodenum to properly absorb nutrients and vitamins that would otherwise be lost in the feces. 35 Poor growth may be avoided by insertion of a feeding tube for increasing calories through supplemental feeds or by administration of injected growth hormone. 36 
